Inhibrx Biosciences, Inc.
INBX
$14.00
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.12% | -102.40% | 3,811.11% | 47.36% | -80.74% |
| Total Depreciation and Amortization | -9.34% | 59.66% | 32.22% | 20.81% | -1.97% |
| Total Amortization of Deferred Charges | -- | -100.00% | -- | -- | 0.65% |
| Total Other Non-Cash Items | -0.32% | 100.18% | -35,517.67% | -19.98% | -1.33% |
| Change in Net Operating Assets | -99.96% | -76.36% | 1,181.01% | -89.10% | 358.36% |
| Cash from Operations | -44.38% | 62.19% | -98.68% | 29.05% | -4.75% |
| Capital Expenditure | 93.52% | 79.67% | -8.58% | 67.49% | -324.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 93.52% | 79.67% | -8.58% | 67.49% | -324.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -99.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -200.00% | 18,514.67% | -73.08% |
| Cash from Financing | -- | -100.00% | -27.00% | 4,717.79% | -99.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.27% | 40.22% | -- | -- | -141.01% |
